# AbbVie Inc. (ABBV) — capital_raise/public_offering [announced]
Source: sec.gov · situation sit_09134815610c77879072 · public 3337274370012584054 · retrieved 2026-08-19T13:18:52.378Z

## Overview
AbbVie Inc. is a pharmaceutical company that develops and markets a broad portfolio of medicines and therapies.

On August 18, 2026, AbbVie Inc. completed an underwritten public offering of $8,500,000,000 in aggregate principal amount of senior notes across nine series: $500,000,000 floating rate notes due 2028, $1,000,000,000 4.500% notes due 2028, $1,250,000,000 4.650% notes due 2030, $1,500,000,000 4.875% notes due 2031, $1,250,000,000 5.050% notes due 2033, $1,500,000,000 5.300% notes due 2036, $1,000,000,000 5.450% notes due 2038, $1,500,000,000 6.000% notes due 2056, and $500,000,000 6.100% notes due 2066. The offering was conducted in connection with AbbVie's previously announced acquisition of Apogee Therapeutics, Inc., with net proceeds to be used to fund a portion of the aggregate cash consideration due to Apogee shareholders and to pay related fees and expenses.

## Terms
- Counterparty: Apogee Therapeutics, Inc. · Consideration: cash

## Key dates
- Announced 2026-08-18

## Timeline
- 2026-08-18 · 8-K (0001104659-26-098367): 8-K - AbbVie Inc. — *AbbVie Inc. is a pharmaceutical company that develops and markets a broad portfolio of medicines and therapies.* On August 18, 2026, AbbVie Inc. completed an underwritten public offering of $8,500,000,000 in aggregate principal amount of senior notes across nine series: $500,000,000 floating rate notes due 2028, $1,000,000,000 4.500% notes due 2028, $1,250,000,000 4.650% notes due 2030, $1,500,000,000 4.875% notes due 2031, $1,250,000,000 5.050% notes due 2033, $1,500,000,000 5.300% notes due 2036, $1,000,000,000 5.450% notes due 2038, $1,500,000,000 6.000% notes due 2056, and $500,000,000 6.100% notes due 2066. The offering was conducted in connection with AbbVie's previously announced acquisition of Apogee Therapeutics, Inc., with net proceeds to be used to fund a portion of the aggregate cash consideration due to Apogee shareholders and to pay related fees and expenses.
  https://www.sec.gov/Archives/edgar/data/1551152/0001104659-26-098367.txt

## Citations
- 0001104659-26-098367 — https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&type=&dateb=&owner=include&count=40&search_text=000110465926098367